Skip to main content

A new study led by Christine Rini, PhD, finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

A new study Icon indicating that a link will open an external site. finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

The process includes first writing for oneself in emotionally expressive ways about the trauma of the cancer and transplant experience, followed by peer helping, which includes writing as if speaking to a person ready to undergo the transplant procedure about the survivor’s experience while offering advice and encouragement.

Christine Rini, PhD, research associate professor of health behavior at the UNC Gillings School of Global Public Health and member of the UNC Lineberger Comprehensive Cancer Center, led the study.

Benefits of receiving peer support when in ill health are recognized widely. Although fewer studies have focused upon the effect of an ill person’s giving support to a peer, prior research has established that cancer survivors who help others face treatment experience a range of psychosocial and health-related benefits as a result of peer helping. The current study shows that the survivor’s preceding the helping with emotionally expressive writing about his or her own experiences increases the health benefits to the survivor.

Rini and colleagues designed a four-part trial that compared expressive helping with neutral writing for oneself, expressive writing for oneself and peer helping (writing as if speaking to a person ready to undergo transplant, without first doing expressive writing for oneself).

Post-intervention, the survivor-participants were evaluated for levels of general psychological distress, physical symptoms and health-related quality of life. These measures were chosen specifically because the toxicity of hematopoietic stem cell transplant causes fatigue, cognitive problems and psychological distress that can last for months or years, diminishing quality of life. The researchers wanted to determine which interventions might benefit those survivors who had surpassed acute treatment but were still suffering moderate to severe survivorship problems.

Among survivors with moderate to severe survivorship problems, the expressive helping process, which combined expressive writing for oneself and peer helping by writing for others, reduced distress and improved physical symptoms and quality of life, compared to the helping or writing processes alone.

“We think that expressive helping helps transplant survivors translate their experience into language so they can develop a more coherent narrative of their experience and greater insight into its meaning,” Rini said. “Research shows that expressive writing has those kinds of benefits. In turn, that should help prepare survivors to communicate their experience to others in a way that provides more meaningful peer support.”

The study sample included 178 women and 137 men, an average 20 months post-transplant, recruited between 2008 and 2011 from survivors at Mount Sinai and Hackensack University medical centers. Consistent with the population receiving stem cell transplant in the U.S., most were white, partnered, college-educated and with moderately high income.

Co-authors include Jane Austin, PhD, associate professor of psychology at William Paterson University; Lisa M. Wu, PhD, instructor of oncological sciences, Gary Winkel, PhD, research professor of oncological sciences, Luis Isola, MD, professor of medicine, hematology and medical oncology, and William H. Redd, PhD, professor of oncological sciences, all of Mount Sinai’s Icahn School of Medicine; Heiddis Valdimarsdottir, PhD, professor of health education at Reykjavik University; Annette L. Stanton, PhD, professor of psychology/psychiatry at University of California at Los Angeles; and Scott Rowley, MD, chief of the John Theurer Cancer Center’s Blood and Marrow Stem Cell Transplantation Division at Hackensack (N.J.) University Medical Center.

Date: Nov. 26, 2013